China Digest: Lynk Pharma, Bestzyme Bioengineering bag funds
Biopharmaceutical firm Lynk Pharmaceuticals has bagged 200 million yuan ($28.2 million) in its Series C1 round, according to a release.
Source: dealstreetasia.com
Stay updated with breaking news from Bestzyme Bioengineering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biopharmaceutical firm Lynk Pharmaceuticals has bagged 200 million yuan ($28.2 million) in its Series C1 round, according to a release.